Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress(TM) 2017; -- 12-Week Results with the Investigational ACC Inhibitor Show Inhibition of De Novo Lipogenesis and Significant Reducti

Press/Media: Press / Media

PeriodApr 21 2017

Media coverage

2

Media coverage

  • TitleGilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress(TM) 2017; -- 12-Week Results with the Investigational ACC Inhibitor Show Inhibition of De Novo Lipogenesis and Significant Reducti
    Media name/outletBusiness Wire
    CountryUnited States
    Date4/21/17
    PersonsEric J Lawitz
  • TitleGilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress(TM) 2017; -- 12-Week Results with the Investigational ACC Inhibitor Show Inhibition of De Novo Lipogenesis and Significant Reducti
    Media name/outletBusiness Wire
    CountryUnited States
    Date4/21/17
    PersonsEric J Lawitz